Anatara Lifesciences Ltd (ASX: ANR) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Anatara Lifesciences Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$8.73 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
207.89 million
Earnings per share
-0.010
Dividend per share
N/A
Year To Date Return
127.27%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Anatara Lifesciences Ltd (ASX: ANR)
Latest News
Share Market News
Why the Anatara (ASX:ANR) share price is rocketing 19% today
⏸️ Investing
5 multi-million dollar takeover targets
⏸️ Investing
Ham and pineapple could make Anatara Lifesciences Ltd the next CSL Limited
⏸️ Investing
10 stocks up by more than 50% in the past month
ANR ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Anatara Lifesciences Ltd
Anatara Lifesciences Ltd. engages in the development of non-antibiotic oral solutions for gastrointestinal diseases in animals and humans. It also develops and commercializes Detach, a non-antibiotic therapy that prevents and treats diarrhea in piglets. The company was founded by Tracey Mynott on July 15, 2010 and is headquartered in North Melbourne, Australia.
ANR Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 24 Dec 2024 | $0.04 | $-0.01 | -20.00% | 144,644 | $0.05 | $0.05 | $0.04 |
| 23 Dec 2024 | $0.05 | $0.00 | 0.00% | 23,999 | $0.05 | $0.05 | $0.05 |
| 20 Dec 2024 | $0.05 | $0.00 | 0.00% | 28,600 | $0.05 | $0.05 | $0.05 |
| 19 Dec 2024 | $0.05 | $0.00 | 0.00% | 32,541 | $0.05 | $0.05 | $0.05 |
| 18 Dec 2024 | $0.05 | $0.00 | 0.00% | 30,500 | $0.05 | $0.05 | $0.05 |
| 17 Dec 2024 | $0.05 | $0.00 | 0.00% | 21,000 | $0.05 | $0.05 | $0.05 |
| 16 Dec 2024 | $0.05 | $0.00 | 0.00% | 34,831 | $0.05 | $0.05 | $0.05 |
| 13 Dec 2024 | $0.05 | $0.00 | 0.00% | 158,924 | $0.05 | $0.05 | $0.05 |
| 12 Dec 2024 | $0.05 | $0.00 | 0.00% | 11,000 | $0.05 | $0.05 | $0.05 |
| 11 Dec 2024 | $0.05 | $0.00 | 0.00% | 300,000 | $0.05 | $0.05 | $0.05 |
| 10 Dec 2024 | $0.05 | $0.00 | 0.00% | 71,687 | $0.05 | $0.05 | $0.05 |
| 09 Dec 2024 | $0.05 | $0.00 | 0.00% | 73,263 | $0.05 | $0.05 | $0.05 |
| 06 Dec 2024 | $0.05 | $0.00 | 0.00% | 68,015 | $0.05 | $0.05 | $0.05 |
| 05 Dec 2024 | $0.05 | $0.00 | 0.00% | 187,006 | $0.05 | $0.05 | $0.05 |
| 04 Dec 2024 | $0.05 | $-0.01 | -17.54% | 227,437 | $0.06 | $0.06 | $0.05 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 18 Nov 2024 | John Michailidis | Issued | 359,640 | $20,859 |
Issue of securities. 359,640 Performance Rights
|
| 09 Jul 2024 | Nicholas Haslam | Issued | 1,000,000 | $40,000 |
Issue of options.
|
| 09 Jul 2024 | David Brookes | Issued | 1,500,000 | $60,000 |
Placement.
|
| 09 Jul 2024 | David Brookes | Issued | 2,500,000 | $100,000 |
Issue of options. As per announcement on 12-07-2024
|
| 09 Jul 2024 | John Michailidis | Issued | 250,000 | $10,000 |
Placement.
|
| 09 Jul 2024 | John Michailidis | Issued | 1,000,000 | $40,000 |
Issue of options.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Dr David Lionel Brookes | Executive ChairmanExecutive Director | Jun 2022 |
Dr Brookes has experience in the health and biotechnology industries, first becoming involved in the biotechnology sector in the late 1990's as an analyst. Brookes has since held Board positions in a number of ASX listed biotechnology companies, including as Chairman of genomics solutions company, RHS Ltd, which was acquired by Perkin Elmer Inc (NYSE:PKI) in June 2018. He has also Chaired the risk and audit committees in ASX listed companies. He is member of Risk Management Committee.
|
| Mr John Michailidis | Chief Operating OfficerExecutive Director | Oct 2023 |
Mr Michailidis has over 30 years of experience in the healthcare, pharmaceutical and biotechnology industries both in Australia and internationally. He has a record in business transformation, entrepreneurship, translation and commercialisation of science organisations, government engagement and influence, effectiveness in research translation, business development and organisational responsibility
|
| Mr Nicholas William Haslam | Non-Executive Director | Dec 2022 |
Mr Haslam has ten years of experience in professional services with M&A and restructuring at PwC, before undertaking leadership roles in professional sports and medical device companies. With respect to medical experience, Nick is formerly the Chief Executive Officer of Plasma Shield Limited, an Australian air decontamination company, as well as commercial manager of KangaTech Pty Ltd, an injury prevention business, with customers spread across Australia, the US, and Europe. He is Chair of Risk Committee.
|
| Mr Jonathan W Lindh | Company Secretary | Nov 2024 |
-
|
| Mr Steven Lydeamore | Chief Executive Officer | Dec 2018 |
-
|
| Simon Erskine | Chief Development Director |
-
|
|
| Steven Lydeamore | Chief Executive Officer |
-
|
|
| John Michailidis | Chief Operator Officer |
-
|
|
| Michael West | Chief Scientific Officer |
-
|
|
| Jonathan W Lindh | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| RTL Group Investments Pty Ltd <The Rtl Investment A/C> | 22,000,000 | 11.41% |
| Ubs Nominees Pty Ltd | 16,642,732 | 8.63% |
| Scintilla Strategic Investments Limited | 8,000,000 | 4.15% |
| Himstedt & Co Pty Ltd <The Himstedt Family A/C> | 6,900,000 | 3.58% |
| Parma Corporation Pty Ltd | 5,576,771 | 2.89% |
| RTL Group Investments Pty Ltd <The Rtl Investment A/C> i | 5,000,000 | 2.59% |
| Mr Samuel Francis Hunter | 4,862,662 | 2.52% |
| John Dahlsen Superannuation Fund Pty Ltd | 4,200,000 | 2.18% |
| Mousetrap Nominees Pty Ltd <Michael Whiting Family A/C> | 3,953,053 | 2.05% |
| Mr Michael Andrew Whiting and Mrs Tracey Anne Whiting <Whiting Family S/F A/C> | 3,625,000 | 1.88% |
| Myeng Pty Ltd | 3,580,211 | 1.86% |
| Calama Holdings Pty Ltd <Mambat Super Fund A/C> | 3,371,940 | 1.75% |
| Symington Pty Ltd | 3,340,000 | 1.73% |
| Toucan Trading Pty Ltd | 3,097,955 | 1.61% |
| Longridge Partners Pty Ltd | 2,839,248 | 1.45% |
| Mr Brendan Phyland | 2,651,659 | 1.37% |
| Mr Andre Nicholas Marschke and Mrs Shaleah Ann Marschke <Anm S/F A/C> | 2,600,000 | 1.35% |
| Octifil Pty Ltd | 2,595,416 | 1.35% |
| Tarandi 1996 Pty Ltd <Dr Dl Brookes Super A/C> | 2,490,002 | 1.29% |
| Mr David Lionel Brookes and Mrs Elisabeth Mary Brookes <Dahlbrook Family A/C> | 2,300,000 | 1.19% |
